Skip to content
OpenCapital
Get started

Dianthus Therapeutics DNTH Clinical Operation Activities — Claseprubart Program Related Expenses

Similar metrics at other companies

Nuvalent, Inc. logo
NUVLNeladalkib — Direct Expenses Related To Program
$26.32M-6.0%
BillionToOne, Inc. logo
BLLNAccrued clinical expenses
$224K—
LQD
LQDAGeneric Treprostinil — Program Expenses
-$49K-132%
Nuvalent, Inc. logo
NUVLDiscovery Programs — Direct Expenses Related To Program
$2.8M+31.4%
Bristol-Myers Squibb logo
BMYR&D
$2.65B+17.4%
Roivant Sciences logo
ROIVBrepocitinib — Research and development (includes $18,123and $9,685 of share-based compensation expense for the three months ended December 31, 2025 and 2024 and $40,218and $30,128 for the nine months ended December 31, 2025 and 2024, respectively)
$14.34M+9.7%

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$4.51B+662%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0×0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept dnth:ClaseprubartProgramRelatedExpenses.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's clinical operation activities — claseprubart program related expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's clinical operation activities — claseprubart program related expenses?
Dianthus Therapeutics (DNTH) reported clinical operation activities — claseprubart program related expenses of $14.16M in Q1 2026.
What does clinical operation activities — claseprubart program related expenses mean?
This metric represents the direct research and development expenditures specifically allocated to the clinical advancement of the claseprubart therapeutic candidate. It encompasses costs related to clinical trial execution, patient recruitment, and regulatory documentation necessary to progress the asset through clinical development phases. Monitoring these expenses provides insight into the capital intensity and development velocity of the company's lead pipeline assets.